SCHEMBL198259

SCHEMBL198259

Cn1c(-c2ccncc2)cc(=O)n1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.54
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 3/20 0.42
GAA P10253 2/20 0.42
NR4A2 P43354 1/20 0.41
GSK3B P49841 5/20 0.39
CDC7 O00311 2/20 0.39
ROCK2 O75116 1/20 0.39
MAP4K4 O95819 1/20 0.39
PIM1 P11309 1/20 0.39
PRKACA P17612 1/20 0.39
HIPK2 Q9H2X6 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
NOTUM Q6P988 1/20 0.38
TSHR P16473 1/20 0.38
FLT3 P36888 1/20 0.38
BCHE P06276 1/20 0.37
PTGS2 P35354 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK9 P45984 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11071487 0.89 NAPRT (0.62) NAPRTALDH1A1GSK3BTSHRBCHE
SCHEMBL1758432 0.75 NAPRT (0.53) NAPRTALDH1A1GSK3BTSHRBCHE
Antipyrine SCHEMBL20452 0.71 NAPRT (1.00) NAPRTKDM4EALDH1A1GSK3BTSHR
SCHEMBL1964715 0.70 ALDH1A1 (0.46) NAPRTKDM4EALDH1A1GSK3BTSHR
Antipyrine SCHEMBL8736656 0.69 NAPRT (0.96) NAPRTKDM4EALDH1A1GSK3BTSHR
SCHEMBL7842787 0.69 NAPRT (0.65) NAPRTKDM4EALDH1A1GAAGSK3B
Antipyrine SCHEMBL18260589 0.69 NAPRT (0.96) NAPRTKDM4EALDH1A1GSK3BTSHR
Antipyrine SCHEMBL28445203 0.69 NAPRT (0.96) NAPRTKDM4EALDH1A1GSK3BTSHR
Antipyrine SCHEMBL8995343 0.69 NAPRT (0.96) NAPRTKDM4EALDH1A1GSK3BTSHR
Antipyrine SCHEMBL7020007 0.69 NAPRT (0.96) NAPRTKDM4EALDH1A1GSK3BTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
EP-1881976-B1 SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS AMGEN INC (US) 2012-10-17 EP disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES KIM TAE-SEONG (US) 2012-03-22 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-8088794-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2012-01-03 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7858623-B2 Substituted amide derivatives and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed
US-20080312232-A1 Substituted amide derivatives and methods of use AMGEN INC. (US) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312232-A1 Substituted amide derivatives and methods of use HGF, HGFAC, MET NAPRT 467/4885KDM4E 3651/4885ALDH1A1 76/4885
US-20120070413-A1 METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES HGF, HGFAC, MET NAPRT 463/4885KDM4E 3048/4885ALDH1A1 58/4885
US-20110118252-A1 SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE HGF, HGFAC, MET NAPRT 467/4885KDM4E 3651/4885ALDH1A1 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.